Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "Benefits"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"Canadian Agency for Drugs and Technologies in Health"
dewey-ones:"140 - Specific philosophical schools"
dewey-ones:"330 - Economics"
language:"English"
Showing
1
-
19
of
19
Search:
'"Benefits"'
,
query time: 0.02s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
2
Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
3
Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
4
Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
5
Pharmacoeconomic review report: Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)
Published 2017
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
6
Pharmacoeconomic review report: Sarilumab (Kevzara)
Published 2017
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
7
CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis
Published 2020
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
8
CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
9
CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
10
Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication: for the treatment of adult patients with active ankylosing spondylitis who have responded i...
Published 2020
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
11
High dose influenza vaccine for adults : a review of clinical effectiveness, cost-effectiveness, and guidelines
by
Wells, Charlotte
,
Grobelna, Aleksandra
Published 2019
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
12
High dose influenza vaccine for adults : a review of clinical effectiveness, cost-effectiveness, and guidelines
by
Wells, Charlotte
,
Grobelna, Aleksandra
Published 2019
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
13
Pharmacoeconomic report: Vedolizumab (Entyvio SC) Takeda Canada Inc. : indication : for the treatment of adult patients with moderately to severely active ulcerative colitis who ha...
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
14
Pharmacoeconomic review report: Belimumab (Benlysta) (GlaxoSmithKline Inc.) : indication: indicated in addition to standard therapy for reducing disease activity in adult patients...
Published 2020
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
15
Pharmacoeconomic review report: Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
16
CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
17
CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
18
Biologics versus immunomodulators or antibiotics for the management of fistulizing Crohn's disease : a review of comparative clinical effectiveness and cost-effectiveness
by
Young, Calvin
,
Campbell, Kaitryn
Published 2019
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
19
Biologics versus immunomodulators or antibiotics for the management of fistulizing Crohn's disease : a review of comparative clinical effectiveness and cost-effectiveness
by
Young, Calvin
,
Campbell, Kaitryn
Published 2019
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Back
Narrow Search
Remove Filters
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Clear Filter
Classification: 140 - Specific philosophical schools
Clear Filter
Classification: 330 - Economics
Clear Filter
Language: English
Year of Publication
From:
To:
Classification
140 - Specific philosophical schools
330 - Economics
610 - Medicine & health
7
700 - The arts; fine & decorative arts
5
Language
English
Collection
National Center for Biotechnology Information
19
Author
Canadian Agency for Drugs and Technologies in Health
CADTH Canadian Drug Expert Committee
5
Canadian Agency for Drugs and Technologies in Health Rapid Response Service
4
Campbell, Kaitryn
2
Grobelna, Aleksandra
2
Wells, Charlotte
2
more ...
Young, Calvin
2
see all ...
less ...
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&filter%5B%5D=dewey-ones%3A%22140+-+Specific+philosophical+schools%22&filter%5B%5D=dewey-ones%3A%22330+-+Economics%22&filter%5B%5D=language%3A%22English%22&lookfor=%22Benefits%22&type=Subject
Send by Email
×
Loading...